Dextromethorphan-bupropion, a novel oral N-methyl-D-aspartate receptor antagonist approved by the Food and Drug Administration in August 2022, launched in the United States in October 2022 for major depressive disorder. We aimed to detect and characterize the adverse events (AEs) of dextromethorphan-bupropion using the FDA adverse event reporting system from the 4th quarter of 2022 to the 4th...
Esketamine nasal spray (ESK-NS) is a new drug for treatment-resistant depression, and we aimed to detect and characterize the adverse events (AEs) of ESK-NS using the Food and Drug Administration (FDA) adverse event reporting system (FAERS) database between 2019 Q1 and 2023 Q4. Reporting odds ratio (ROR), proportional reporting ratio (PRR), and multi-item gamma Poisson shrinker (MGPS) were...